Drugs / CpG-MCL vaccine
CpG-MCL vaccine
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT00490529 | Aug 2009 → Dec 2017 | mantle cell lymphoma | Ronald Levy | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CpG-MCL vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00490529 ↗ |
| Known as | Cytosine-Guanosine repeats (CpG)-mantle cell lymphoma (CpG-MCL vaccine) | “Cytosine-Guanosine repeats (CpG)-mantle cell lymphoma (CpG-MCL vaccine)” NCT00490529 ↗ |
| Modality | Vaccine | “CpG-MCL vaccine is a vaccine prepared by co-culturing cells from the participant's mantle cell lymphoma suspension” NCT00490529 ↗ |
| Route | Subcutaneous | “1 x 10e8 CpG-MCL cells will be given as a subcutaneous injection” NCT00490529 ↗ |